For GI carcinomas and variety of other cancers, we observed that both cancerous and matched normal tissues manifested balanced NKp30c inhibitory and NKp30a/b activation profiles; yet, we found skewed NKp30 splice variant profiles in about 50% of a variety of tumor tissues compared to their matched normal tissues (95). The gene discussed is NCR3; the disease is cancer.